Marginal Zone Lymphoma (MZL) Clinical Trials

• Age ≥18 years, regardless of gender;

• Patients with histopathologically confirmed stage I/II marginal zone lymphoma;

• ECOG performance status score of 0-2;

• Major organ functions meeting the following criteria:

‣ Blood tests: Absolute neutrophil count (ANC) ≥1.5×10\^9/L, platelets ≥75×10\^9/L, hemoglobin ≥75g/L; if accompanied by bone marrow involvement, ANC ≥1.0×10\^9/L, platelets ≥50×10\^9/L, hemoglobin ≥50g/L;

⁃ Blood biochemistry: Total bilirubin ≤1.5×ULN, AST or ALT ≤2×ULN; serum creatinine ≤1.5×ULN;

• Coagulation function: International normalized ratio (INR) ≤1.5×ULN;

• Expected survival time ≥12 months;

• Voluntary written informed consent signed before trial screening.